Emerging Therapeutic Targets in Breast Cancer Bone Metastasis
Authors:
- 18 December 2009
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 6 (1) , 55-74
Abstract
In the past decade, our understanding of the molecular mechanisms that underlie breast cancer pathology and progression has dramatically improved. Using this knowledge, we have identified additional targets and developed novel therapeutic interventions in breast cancer. Together, these translational research efforts are helping to usher us into an age of personalized cancer therapy. Metastasis to bone is a common and devastating consequence of breast cancer. Bisphosphonates, which represent the current gold standard in bone metastasis therapies, are being improved with newer and more efficacious generations of these compounds being developed. Breast cancer growth in the bone requires activation of various signaling pathways in both cancer cells and stromal cells, including those that are stimulated by TGF-beta and RANKL, and mediated through the Src tyrosine kinase. Bone cells and cancer cells alike express promising targets for therapeutic intervention, including Cathepsin K, CXCR4 and GPNMB. In this article we discuss the molecular mechanisms behind these pro-metastatic molecules and review the most recent findings in the clinical development of their associated targeted therapies.Keywords
This publication has 159 references indexed in Scilit:
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysisBritish Journal of Cancer, 2009
- Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival SignalsCancer Cell, 2009
- The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclastsBone, 2009
- The DC‐HIL/syndecan‐4 pathway inhibits human allogeneic T‐cell responsesEuropean Journal of Immunology, 2009
- The metastatic niche: adapting the foreign soilNature Reviews Cancer, 2009
- TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4Cell, 2008
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote MetastasisCancer Cell, 2008
- Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivityBritish Journal of Cancer, 2006
- Regulation of cancer cell migration and bone metastasis by RANKLNature, 2006
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004